Floatz logo

Nivolumab

Differentiated Thyroid Carcinoma

Exelixismonoclonal_antibodyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Differentiated Thyroid Carcinoma cohort.

Asset / SponsorPhaseRating
Bms-907351
Exelixis
Phase 3BB
Atezolizumab
Exelixis
Phase 3BB
Enzalutamide
Exelixis
Phase 3B
PREDNISONE TABLETS
Exelixis
Phase 3B
Abiraterone Acetate
Exelixis
Phase 3B

View all 13 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →